David L. Hallal's most recent trade in Scholar Rock Holding Corp was a trade of 128,004 Common Stock done . Disclosure was reported to the exchange on Feb. 9, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | David L. Hallal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2026 | 128,004 | 1,669,649 (5%) | 0% | 0 | Common Stock | |
| Scholar Rock Holding Corp | David L. Hallal | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 42.70 per share. | 13 Jan 2026 | 57,450 | 1,541,645 (5%) | 0% | 42.7 | 2,453,115 | Common Stock |
| Scholar Rock Holding Corp | David L. Hallal | Director, Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 08 Oct 2025 | 205,000 | 1,599,095 (5%) | 0% | 0 | Common Stock | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2025 | 38,228 | 0 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Sale of securities on an exchange or to another person at price $ 10.24 per share. | 04 Jun 2025 | 38,228 | 0 | - | 10.2 | 391,455 | Common Stock |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 04 Jun 2025 | 38,228 | 38,228 | - | 4.3 | 164,380 | Common Stock |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 04 Jun 2025 | 38,227 | 38,227 | - | 4.3 | 164,376 | Common Stock |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2025 | 38,227 | 38,228 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jun 2025 | 38,227 | 76,455 | - | - | Stock Option (Right to Buy) | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Sale of securities on an exchange or to another person at price $ 10.15 per share. | 04 Jun 2025 | 38,227 | 0 | - | 10.1 | 388,004 | Common Stock |
| ITeos Therapeutics Inc | David L. Hallal | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.30 per share. | 04 Jun 2025 | 38,227 | 38,227 | - | 4.3 | 164,376 | Common Stock |
| ITeos Therapeutics Inc | David L. Hallal | Director | Sale of securities on an exchange or to another person at price $ 10.07 per share. | 04 Jun 2025 | 38,227 | 0 | - | 10.1 | 384,946 | Common Stock |
| Scholar Rock Holding Corp | David L. Hallal | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2025 | 275,167 | 275,167 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 1,250,000 | 1,804,095 (6%) | 4% | 0 | Common Stock | |
| Scholar Rock Holding Corp | David L. Hallal | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2025 | 250,000 | 554,095 (1%) | 0% | 0 | Common Stock | |
| Kalaris Therapeutics Inc | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 18,000 | 18,000 | - | - | Stock Option (Right to Buy) | |
| Scholar Rock Holding Corp | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 13,500 | 304,095 (1%) | 0% | 0 | Common Stock | |
| Seer Inc (Class A) | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2024 | 58,178 | 355,128 | - | 0 | Class A Common Stock | |
| ITeos Therapeutics Inc | David L. Hallal | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 24,200 | 24,200 | - | - | Stock Option (Right to Buy) | |
| Kalaris Therapeutics Inc | David L. Hallal | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 35,000 | 2,143,662 | - | 0 | Common Stock |